ReviewNutrition & diabetes2025
Dietary formaldehyde: a silent aggravator of diabetes and cognitive impairments.
Review in Nutrition & diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic effects of type 2 diabetes therapies: an integrated perspective on the cardio-renal- cerebral-metabolic axis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Diabetes mellitus (DM) is a chronic metabolic disorder associated with a range of serious complications, including insulin resistance (IR) and cognitive impairments. IR is recognized as a high-risk factor for the development of cognitive decline. However, it remains unclear which endogenous or exogenous factors induce these two pathological features. Recent studies indicate that certain diets, environmental pollutants, and genetic deficiencies or polymorphisms influence the metabolism of endogenous formaldehyde. Formaldehyde has been implicated in the onset of DM. Notably, elevated levels of formaldehyde have been detected in the blood, peripheral organs (such as the spleen and liver), and brains of both DM patients and animal models of diabetes. Formaldehyde-induced hyperglycemia and high glucose levels generate formaldehyde, creating a vicious cycle that speeds up diabetic complications. Further, excessive formaldehyde induces IR through three distinct mechanisms: alteration of the biologically active conformation of insulin, reduction in insulin receptor expression, and modification of insulin receptor structure. In addition, excessive formaldehyde can impair cognitive functions by inhibiting N-methyl-D-aspartate (NMDA) receptors and exacerbating brain IR. In this review, we discuss the pivotal role of diet-derived formaldehyde in diabetes and propose that reduction of formaldehyde by the formaldehyde scavengers may be a new strategy for treating DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.